{"id":1324,"date":"2013-07-01T12:03:00","date_gmt":"2013-07-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/zweitlinientherapie-der-rheumatoiden-arthritis-nach-versagen-von-methotrexat"},"modified":"2013-07-01T12:03:00","modified_gmt":"2013-07-01T10:03:00","slug":"zweitlinientherapie-der-rheumatoiden-arthritis-nach-versagen-von-methotrexat","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/zweitlinientherapie-der-rheumatoiden-arthritis-nach-versagen-von-methotrexat","title":{"rendered":"Zweitlinientherapie der Rheumatoiden Arthritis nach Versagen von Methotrexat"},"content":{"rendered":"<p>Die Prognose der Patienten mit Rheumatoider Arthritis (RA) ist in den letzten 20 Jahren deutlich besser geworden (1). Dazu haben eine fr\u00fchere Diagnose und bessere medikament\u00f6se Behandlungsm\u00f6glichkeiten beigetragen (2). Zu den Wirkstoffen z\u00e4hlen Methotrexat (MTX), Sulfasalazin und Hydroxychloroquin (= sog. Disease-Modifying Antirheumatic Drugs = DMARDs = Basistherapeutika) sowie Biopharmazeutika (biologische DMARDs), die meist gegen Entz\u00fcndungsmediatoren [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Prognose der Patienten mit Rheumatoider Arthritis (RA) ist in den letzten 20 Jahren deutlich besser geworden (1). Dazu haben eine fr\u00fchere Diagnose und bessere medikament\u00f6se Behandlungsm\u00f6glichkeiten beigetragen (2). Zu den Wirkstoffen z\u00e4hlen Methotrexat (MTX), Sulfasalazin und Hydroxychloroquin (= sog. Disease-Modifying Antirheumatic Drugs = DMARDs = Basistherapeutika) sowie Biopharmazeutika (biologische DMARDs), die meist gegen Entz\u00fcndungsmediatoren [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1891,2718,276,3196,1067,712,3197,1257,1260,1261,1258,1264],"class_list":["post-1324","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-etanercept","tag-hydroxychloroquin","tag-methotrexat","tag-racat-studie","tag-rheumatoide-arthritis","tag-sulfasalazin","tag-tear-studie","tag-tnf-alpha-blocker","tag-tnf-alpha-hemmer","tag-tumor-nekrose-faktor-antagonisten","tag-tumor-nekrose-faktor-blocker","tag-tumor-nekrose-faktor-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1324"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1324\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}